Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease

Table 1

Baseline clinical characteristics of patients with diabetes and coronary artery disease after percutaneous coronary intervention.

	Control𝑛=56	Rosiglitazone𝑛=60
Character
Age, years	63.20±7.50	61.60±7.60
Body mass index	25.50±2.70	26.10±2.60
Sex (M/F)	45/10	49/11
Risk factors, no.
Hyperlipidemia	24	26
Hypertension	41	42
Smoking	23	28
Parameters (levels)
Cholesterol, mmol/L	4.80±0.57	4.85±0.48
High-density lipoprotein, mmol/L	1.02±0.15	1.04±0.12
Low-density lipoprotein, mmol/L	2.87±0.63	2.93±0.78
Triglycerides, mmol/L	2.01±0.70	1.99±0.63
Fasting insulin, m𝜇/L	11.40±1.72	13.10±1.84
Fasting plasma glucose, (mmol/L)	7.20±1.35	7.10±1.42
HbA1c, %	7.23±0.68	7.15±0.72
HOMA-IR	3.85±0.38	4.12±0.38
CRP, mg/dL	1.84±0.21	1.66±0.23
sICAM-1, ng/mL	407.1 (344.3–476.1)	423.5 (327.4–421.9)
sP-selectin, ng/mL	172.6 (123.3–223.3)	182.5 (127.2–212.9)
Medication
Aspirin	55	60
B-blocker	51	53
Lipid-lowering drugs	51	58
Nitrates	24	23
Ca-Antagonists	7	7
ACE inhibitors	43	43
Other antidiabetic drugs	34	35
Biguanides	22	24
Acarbose	8	8
Sulfonylureas	4	5

HOMA-IR: homeostasis-model-assessment insulin resistance; CRP: C-reactive protein; sICAM-1: soluble intercellular adhesion molecule-1; HbA1c: hemoglobin A1c; sP-selectin: soluble P selectin. Data are means ± SD or medians and ranges.